Journal article

Vasopressin V-1A receptor antagonism does not reverse adrenocorticotrophin-induced hypertension in the rat

TB Fraser, SW Turner, C Wen, M Li, LM Burrell, JA Whitworth

Clinical and Experimental Pharmacology and Physiology | BLACKWELL SCIENCE ASIA | Published : 2000


1. The role of arginine vasopressin (AVP) was examined in adrenocorticotrophin (ACTH)-induced hypertension in Sprague-Dawley rats using the non-peptide AVP V1a receptor antagonist OPC 21268. 2. In an acute study, six rats were pretreated with ACTH for 11 days and direct arterial blood pressure (4 h), plasma osmolality and electrolyte concentrations were measured after OPC 21268 gavage. In a chronic study, 40 rats were randomly divided into four groups: (i) sham injection + sham gavage; (ii) ACTH + sham gavage; (iii) sham injection + OPC 21268; or (iv) ACTH + OPC-21268 for 16 days. Systolic blood pressure (SBP), water intake, urine volume (UV), urine osmolality and electrolytes, food intake, ..

View full abstract

University of Melbourne Researchers